Genmab
GMAB
223 hedge funds and large institutions have $1.28B invested in Genmab in 2024 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 98 increasing their positions, 66 reducing their positions, and 24 closing their positions.
48% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 66
21% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 24
5.35% more ownership
Funds ownership: 73.7% → 79.04% (+5.3%)
2% more funds holding
Funds holding: 219 → 223 (+4)
4% more capital invested
Capital invested by funds: $1.23B → $1.28B (+$51.5M)
59% less call options, than puts
Call options by funds: $256K | Put options by funds: $626K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
+$44.8M |
| 2 |
Morgan Stanley
New York
|
+$16.3M |
| 3 |
Renaissance Technologies
New York
|
+$8.66M |
| 4 |
HL
Harding Loevner
Bridgewater,
New Jersey
|
+$8M |
| 5 |
Two Sigma Advisers
New York
|
+$7.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$12.4M |
| 2 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$7M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$5.89M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$2.72M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$1.47M |
GMAB Hedge Fund Activity: Q3 2024 in Review
223 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q3 2024, worth a combined $1.28B — up 4.2% from $1.23B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new GMAB positions and 24 closed out — a net gain of 5 holders — while 98 added to existing stakes and 66 trimmed.
The largest buyer was Orbis Allan Gray, opening a new position worth an estimated $44.8M. The largest seller was BlackRock, cutting an estimated $12.4M.
- 223 institutional investors held Genmab (GMAB) as of Q3 2024, up from 219 in Q2 2024.
- Funds reported $1.28B of Genmab stock for Q3 2024, up 4.2% quarter-over-quarter.
- 29 funds opened new Genmab positions in Q3 2024 and 24 closed out, a net change of +5 holders.
- The largest Genmab buyer in Q3 2024 was Orbis Allan Gray, an estimated $44.8M added.
- The largest Genmab seller in Q3 2024 was BlackRock, an estimated $12.4M sold.
Based on aggregated 13F filings for Q3 2024.